In today’s briefing:
- Hugel (145020 KS): South Korea’s Low-Cost Botox Leader Now Expanding to the US
- Korea Small Cap Gem #71: Won Tech
- Oura (OURA US): Oura Steps Into the IPO Spotlight, Sets Terms With $14B+ Valuation Target
- Weekly Update (MMED, MDT, ZD)
- ADARx Pharmaceuticals (ADRX): ADARx Sets Terms, Targets Up to $372m in IPO, AbbVie Alongside
- Zhejiang Jingxin Pharmaceutical (ZJXP HK): Synthetic Expert Call Transcript (21 Sep 2026)
- CooperCompanies’ Hidden Growth Engine — MyDay Keeps Expanding Despite Channel Pressure!
- Lakewood-Amedex Biotherapeutics (LABT US): Synthetic Expert Call Transcript (21 Sep 2026)
- MapLight Therapeutics (MPLT US): Synthetic Expert Call Transcript (21 Sep 2026)
Hugel (145020 KS): South Korea’s Low-Cost Botox Leader Now Expanding to the US
- On Tuesday, Meera Kapoor wrote about how GLP-1 drugs cause people’s skin to become saggy – the effect that’s now popularly known as “Ozempic face”.
- Two solutions are botulinum neurotoxin (“Botox”) and dermal fillers.
- Botox is injected into the skin to reduce wrinkles. Such wrinkles include frown lines, forehead lines and so-called “crow’s feet.
Korea Small Cap Gem #71: Won Tech
- Won Tech’s exports increased by 59.8% YoY in 2025 and by 21.5% YoY in 1H 2026. The company’s export sales to the U.S. increased sharply in 1H 2026.
- Won Tech is currently trading at P/E of 9.8x and P/B of 2.2x based on 2026 consensus earnings estimates (50% to 60% discount to its historical valuation multiples).
- Won Tech provides medical aesthetics and surgical devices. The company’s products specializes in the laser and energy based medical solutions used for skin rejuvenation and face lifting procedures.
Oura (OURA US): Oura Steps Into the IPO Spotlight, Sets Terms With $14B+ Valuation Target
- Oura brings a compelling mix of 74% revenue growth, 5.0 million paid members, strong retention and recurring subscription revenue to the IPO market.
- Cornerstone interest from Eli Lilly and Dragoneer adds another notable dimension to an offering targeting a valuation above $14 billion.
- With Oura serving as the first major technology IPO test after Labor Day, investor demand and pricing will be closely watched.
Weekly Update (MMED, MDT, ZD)
- This week, Corteva and Vylor hosted their respective analyst days.
- Corteva also set the distribution ratio (1:1) for the spin-off, announced a ticker (VYLR), and confirmed expected regular way trading (10/1/2026).
- Meanwhile, Medtronic announced it would distribute its ~90% stake in its diabetes business, MiniMed (MMED), through an exchange offer (MDT shareholders get to decide which stock they want to own).
ADARx Pharmaceuticals (ADRX): ADARx Sets Terms, Targets Up to $372m in IPO, AbbVie Alongside
- ADARx targets a $1.5–$1.7 billion valuation with a $15–$17 IPO range and 21.875 million shares offered.
- AbbVie’s up to $100 million concurrent investment provides a strategic validation point alongside ADARx’s late-stage siRNA pipeline.
- Proceeds will fund multiple clinical programs, led by Phase 3 onvuzosiran and Phase 2 agazisiran development.
Zhejiang Jingxin Pharmaceutical (ZJXP HK): Synthetic Expert Call Transcript (21 Sep 2026)
- The Stagnation of the Generic Core: Zhejiang Jingxin’s core business is locked in structural stagnation, with total revenue dipping 2.14% in 2025 to RMB 4.07 billion and continuing to slide 1.46% to RMB 1.987 billion in 1H2026. The pressure from Volume-Based Procurement (VBP) is relentless, with 38 to 40 of the company’s products now swept into national or regional procurement lists, rendering the generic and API segments a declining-margin volume game.
- Dimdazenil’s Growth versus Competitive Headwinds: While the Class 1 innovative insomnia drug Dimdazenil (Jingnuoning®) achieved strong growth—surging to RMB 195 million in 2025 and hitting RMB 153 million in 1H2026—its long-term commercial peak is highly contested. The drug currently holds a 5.4% market share, but it faces severe encroachment from newly approved dual orexin receptor antagonists (DORAs), notably Eisai’s Lemborexant and Idorsia’s Daridorexant, which do not carry the clinical psychiatric stigma of GABA-targeting compounds.
- Strategic Capital Underfunding: A deep contradiction exists in the company’s capital allocation. While the company executed a massive RMB 609 million share buyback in 2025 (retiring 5.49% of outstanding shares), it simultaneously starved its future pipeline by cutting R&D expenses to RMB 368 million in 2025 (a 9.0% intensity rate) and down to just 8.3% of revenue in 1H2026. The aggressive pursuit of a dual A+H listing in Hong Kong, with the updated prospectus filed on September 18, 2026, is a direct attempt to secure non-dilutive offshore capital to fund clinical trials and late-stage licensing deals that the domestic cash flow can no longer comfortably support.
Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.
CooperCompanies’ Hidden Growth Engine — MyDay Keeps Expanding Despite Channel Pressure!
- CooperCompanies reported third-quarter fiscal 2026 consolidated revenue of $1.066 billion, up 1% year-over-year on both reported and organic bases.
- CooperVision generated $717 million of revenue, essentially flat from a year earlier, while CooperSurgical increased 3% organically to $349 million.
- CooperVision was affected by deliberate reductions in U.S. channel inventory, which are expected to continue weighing on fourth-quarter results.
Lakewood-Amedex Biotherapeutics (LABT US): Synthetic Expert Call Transcript (21 Sep 2026)
- Nu-3 is a modified nucleotide (Bisphosphocin), not a peptide. This is a critical structural distinction that gives it a massive advantage over antimicrobial peptides (AMPs) by avoiding proteolytic degradation in the active wound bed, while maintaining a straightforward, low-cost organic synthesis profile with manageable COGS.
- The company’s capital position is extremely precarious. With only $2,584,774 in cash and $2,000,000 in short-term investments as of June 30, 2026, the runway only extends into Q1 2027. This barely covers the newly initiated Phase 2a trial for infected diabetic foot ulcers (iDFU), making a highly dilutive capital raise or an unfavorable licensing deal almost inevitable before topline data is generated.
- The commercial viability of the AMR sector remains fundamentally broken. Despite the clinical promise of Nu-3’s physical membrane-disrupting mechanism, the lack of passage of the PASTEUR Act leaves the market reliant on volume-driven models. This forces new antimicrobials to compete against cheap generic antibiotics, severely limiting the near-term commercial valuation of the asset.
Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.
MapLight Therapeutics (MPLT US): Synthetic Expert Call Transcript (21 Sep 2026)
- The failure of MapLight’s once-daily (QD) dosing regimen for ML-007C-MA in the Phase 2 ZEPHYR trial is a severe commercial blow. By failing to achieve statistical significance on the primary PANSS endpoint with the QD formulation, MapLight has lost its key point of differentiation against Bristol Myers Squibb’s twice-daily (BID) Cobenfy, forcing MapLight to advance its own BID regimen (210/3 mg BID) into Phase 3.
- Despite an inferior cross-trial efficacy profile compared to Cobenfy, ML-007C-MA retains real-world adherence advantages. While its -4.5 point drug-placebo PANSS difference and 0.37 effect size are weaker than Cobenfy’s -8.4 to -9.6 points, ML-007C-MA has a simple one-dose titration and no fasting requirements. This directly contrasts with Cobenfy, which requires a complex multi-week titration and must be taken on an empty stomach to avoid a 90% drop in trospium absorption that triggers severe gastrointestinal side effects.
- MapLight’s $501.3 million cash position is sufficient to reach Phase 3 readouts but necessitates complete pipeline stagnation. To preserve its runway through 2028 and fund the Phase 3 ZEPHYR-2 trial in schizophrenia and the Phase 2 VISTA trial in Alzheimer’s disease psychosis (ADP), MapLight has been forced to pause all preclinical and discovery-stage programs, including its pre-clinical QD candidate ML-055. Self-launching is highly unviable, making an eventual out-licensing deal or strategic acquisition by a large pharmaceutical player the only logical end-game.
Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
